FDA Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
NS-089/NCNP-02 previously received Rare Pediatric Disease Designation from the FDA in June 2023 and Breakthrough Therapy Designation in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Aug 23
NS-089/NCNP-02 previously received Rare Pediatric Disease Designation from the FDA in June 2023 and Breakthrough Therapy Designation in…
07 Aug 23
The FDA granted approval based on the results of the GATHER1 and GATHER2 Phase 3 clinical trials in…
07 Aug 23
The approval was based on the overall Phase 3 trial in which Arexvy showed a high vaccine efficacy…
07 Aug 23
In the trial, the RET kinase inhibitor showed a clinically meaningful and statistically significant improvement in progression-free survival…
07 Aug 23
BIMERVAX: A booster dose of bivalent recombinant protein vaccine provides immunisation in people over 16 years of age
07 Aug 23
SFD’s development loan will help to provide an integrated medical facility offering secondary medical care to Saint Lucia’s…
04 Aug 23
ERVEBO is a live recombinant viral vaccine that includes a vesicular stomatitis virus backbone deleted for the VSV…
04 Aug 23
The bulk product, worth $96m, will be made and invoiced in 2023, but it will only partially replenish…
03 Aug 23
The programme, which combines Google Cloud's Vertex AI platform with Cognizant’s AI domain expertise and healthcare industry knowledge,…
03 Aug 23
The approval is based on the results of the Phase 3 SUNLIGHT trial in which the combination of…